US › Healthcare

Cue Biopharma (CUE)

US · Healthcare · Biotechnology

$26.60-1.00%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$5.7M

Revenue YoY

+1250.6%

Net profit

$-5.2M

Profit YoY

+57.8%

EPS

$-1.08

EPS estimate

$-3.30

Net margin

-91.1%

EPS came in at -1.08 against a street estimate of -3.30 — a beat of 67.3%.

Key statistics

Market cap

$112.7M

Forward P/E

0.0

P/B

5.24

Book value

$6.64

EPS (TTM)

$-4.53

52-week high

$45.50

52-week low

$4.97

50-day MA

$28.38

200-day MA

$18.14

Beta

2.46

Analyst view

Analysts rate Cue Biopharma a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $115.00.

Shareholding

Insiders

17.96%

Institutions

13.60%

Largest institutional holders

Fund	Stake
Bleichroeder LP	5.41%
Vanguard Capital Management, LLC	1.95%
Lion Point Capital, LP	1.75%
Geode Capital Management, LLC	0.84%
Vanguard Fiduciary Trust Co	0.43%
BlackRock Inc	0.36%
Texas Capital Bank Wealth Management Services Inc	0.32%
ANGELES WEALTH MANAGEMENT, LLC	0.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cue Biopharma — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.